ArticleAnnals of surgical oncology2025
Elevated Carcinoembryonic Antigen Levels Predict Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Referred to Neoadjuvant Therapy.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Surgical Perspectives on Neoadjuvant Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Cancers · 2026Review
- Surgical decision-making in borderline resectable pancreatic cancer in the era of neoadjuvant therapy: from response assessment to individualized operative strategy.Frontiers in surgery · 2026Review
- ASO Author Reflections: Carcinoembryonic Antigen as a Predictor of Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Undergoing Neoadjuvant Therapy.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeoadjuvant therapy (NT) is generally preferred over upfront surgery for borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC), but many patients fail to reach surgical resection. This study evaluates real-world outcomes of NT in BR-PDAC and identifies predictors of failure to proceed to surgery.
methodsA retrospective analysis of patients with resectable and BR-PDAC diagnosed between January 2015 and July 2024 was performed. Patient and disease characteristics were assessed to identify factors associated with NT dropout and failure to achieve surgical resection.
resultsOf 161 BR-PDAC patients, 111 (69%) were referred to NT and 50 (31%) underwent upfront surgery. Among those referred to NT, 78 (70%) completed therapy and underwent resection. Reasons for failure to reach surgery included local tumor progression (39%), newly developed metastases (18%), and intraoperative findings (27%). Patients failing to reach surgery had significantly higher baseline bilirubin, white blood cell count, and carcinoembryonic antigen (CEA) levels. Elevated CEA significantly predicted surgical failure (adjusted odds ratio: 0.68 per 5-unit increase). Local progression was the primary cause of surgical failure in patients with elevated CEA (60%). Patients achieving resection had significantly improved overall survival (OS). There was no significant difference in OS or disease-free survival (DFS) between patients undergoing upfront surgery and those completing NT followed by resection.
conclusionsElevated baseline CEA predicts failure to achieve surgical resection after NT, primarily owing to local progression. Multicenter studies are essential to refine patient selection criteria for upfront surgery and optimize personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.